Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not ach...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
MDPI AG
2020-03-01
|
| Colección: | Pharmaceutics |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/1999-4923/12/3/256 |